Levodopa

Basic Information

Item Value
DrugBank ID DB01235
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 48

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 Rasmussen subacute encephalitis KG + DL
2 PLA2G6-associated neurodegeneration KG + DL
3 myelitis KG + DL
4 transaldolase deficiency KG + DL
5 paralysis agitans, juvenile, of Hunt KG + DL
6 fructose-1,6-bisphosphatase deficiency KG + DL
7 progressive supranuclear palsy-corticobasal syndrome KG + DL
8 Lewy body dementia KG + DL
9 multiple system atrophy, parkinsonian type KG + DL
10 X-linked intellectual disability-ataxia-apraxia syndrome KG + DL
11 lethal infantile mitochondrial myopathy KG + DL
12 X-linked intellectual disability-cerebellar hypoplasia syndrome KG + DL
13 primary progressive freezing gait KG + DL
14 autosomal dominant striatal neurodegeneration type 1 KG + DL
15 CLCN4-related X-linked intellectual disability syndrome KG + DL
16 X-linked intellectual disability-spastic quadriparesis syndrome KG + DL
17 hydrocephaly-cerebellar agenesis syndrome KG + DL
18 syndromic X-linked intellectual disability Chudley-Schwartz type KG + DL
19 intellectual disability, X-linked, syndromic KG + DL
20 X-linked spasticity-intellectual disability-epilepsy syndrome KG + DL
21 X-linked cerebral-cerebellar-coloboma syndrome syndrome KG + DL
22 Paganini-Miozzo syndrome KG + DL
23 NAA10-related syndrome KG + DL
24 MED12-related intellectual disability syndrome KG + DL
25 X-linked intellectual disability, Stocco dos Santos type KG + DL
26 X-linked intellectual disability-hypotonia-movement disorder syndrome KG + DL
27 Prieto syndrome KG + DL
28 intellectual developmental disorder, X-linked, syndromic, Hackmann-Di Donato type KG + DL
29 polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis KG + DL
30 X-linked intellectual disability with hypopituitarism KG + DL
31 lissencephaly type 1 due to doublecortin gene mutation KG + DL
32 Basilicata-Akhtar syndrome KG + DL
33 X-linked intellectual disability-craniofacioskeletal syndrome KG + DL
34 X-linked intellectual disability-precocious puberty-obesity syndrome KG + DL
35 holoprosencephaly 13, X-linked KG + DL
36 retinal dystrophy with or without extraocular anomalies KG + DL
37 parkinson disease, autosomal dominant KG + DL
38 X-linked intellectual disability-acromegaly-hyperactivity syndrome KG + DL
39 myopia X-linked KG + DL
40 congenital disorder of glycosylation with defective fucosylation KG + DL
41 myopia 26, X-linked, female-limited KG + DL
42 Charcot-Marie-Tooth disease, demyelinating, type 1G KG + DL
43 atypical glycine encephalopathy KG + DL
44 parkinsonism with dementia of Guadeloupe KG + DL
45 faciodigitogenital syndrome KG + DL
46 attention deficit-hyperactivity disorder KG + DL
47 syndromic myopia KG + DL
48 blepharospasm KG + DL

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.